Latest Conference Articles

June 1st 2013, 5:15am

ASCO Annual Meeting

The American Society of Clinical Oncology kicked off its 49th Annual Meeting with leaders urging all stakeholders in cancer care to vigorously oppose cuts to vital US biomedical research funding.

May 31st 2013, 1:03pm

ASCO Annual Meeting

Richard Pazdur, MD, from the FDA's Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.

May 16th 2013, 4:55pm

ASCO Annual Meeting

Combining the checkpoint antibodies ipilimumab and nivolumab led to deep tumor regression in approximately one-third of patients with advanced melanoma.

May 15th 2013, 2:07pm

ASCO Annual Meeting

Men with a high level of cardiovascular fitness at middle age had a reduced risk of developing and dying from lung and colorectal cancer later in life.

May 15th 2013, 2:02pm

ASCO Annual Meeting

The novel selective PI3K-delta inhibitor idelalisib produced rapid and prolonged tumor shrinkage in patients with relapsed or refractory chronic lymphocytic leukemia who received the drug as a monotherapy.

May 15th 2013, 2:02pm

ASCO Annual Meeting

Active surveillance following radical orchiectomy is an effective treatment strategy for men with stage I seminoma.

May 15th 2013, 2:01pm

ASCO Annual Meeting

Routine follow-up imaging is of limited value in determining whether patients with diffuse large B-cell lymphoma have experienced a relapse of their disease.

May 15th 2013, 2:00pm

ASCO Annual Meeting

Radiotherapy at a higher-than-standard dose is harmful to patients with locally advanced non-small cell lung cancer who are also getting concurrent and consolidation chemotherapy.

May 15th 2013, 6:07am

ASCO Annual Meeting

An antibody that targets PD-L1 to unleash the body's immune system has demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, setting the stage for an advance in immunotherapy with broad implications for treatment.

May 6th 2013, 4:05pm

AUA Annual Meeting

An estimated 16,000 urologists will be needed to provide specialty care by 2025, but estimates of the number of urologists likely to be in practice at that time range between 6800 and 7400.

May 6th 2013, 2:18pm

AUA Annual Meeting

The American Urological Association outlines clinical guidelines for sequencing castration-resistant prostate cancer therapies based on six "index patients" each with specific disease characteristics.

May 6th 2013, 5:34am

AUA Annual Meeting

The 108th AUA Annual Meeting held May 4-8 in San Diego, California, contained over 2,000 presentations focused on urologic medicine. This entry contains summaries of four abstracts focused on urothelial, testicular, and prostate cancer.

May 5th 2013, 3:52pm

AUA Annual Meeting

Expectant management, which includes active surveillance and watchful waiting, is widely underused in the treatment of prostate cancer in the United States.

April 16th 2013, 5:29am

AUA Annual Meeting

The 108th American Urological Association (AUA) Annual Meeting is being held at the San Diego Convention Center from May 4 - 8, 2013, and features research, guideline updates, and the latest advances in urologic medicine.

March 18th 2013, 2:10pm

Interdisciplinary Prostate Cancer Congress

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, summarizes the development process of an effective immunotherapy for the treatment men with prostate cancer.

March 18th 2013, 1:16pm

Interdisciplinary Prostate Cancer Congress

Hormonal therapies that target androgen are the focus of several ongoing clinical trials for the treatment of advanced prostate cancer, and as more data accrues, clinicians are gaining valuable insight as to how these drugs can best be used to manage the disease.

March 18th 2013, 12:59pm

Interdisciplinary Prostate Cancer Congress

Following the recent flurry of FDA approvals for prostate cancer medications, oncologists are grappling with questions about which combinations or sequences of those therapies might improve outcomes for patients.

March 18th 2013, 6:56am

Interdisciplinary Prostate Cancer Congress

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital, describes the identification of appropriate surrogate endpoints for the evaluation of new therapies for patients with metastatic castration-resistant prostate cancer.

March 14th 2013, 11:54am

PER® Miami Breast Cancer Conference

This year marks the 30th Annual Miami Breast Cancer Conference, a milestone for Daniel A. Osman, MD, and his wife Lois, who together launched the gathering in 1983 with fewer than 100 attendees and a focus on the then relatively new domain of lumpectomies in breast cancer treatment.

March 9th 2013, 4:10pm

PER® Miami Breast Cancer Conference

Donna Shalala, PhD, President, University of Miami, discusses the new healthcare reform in the U.S.